A benefit–risk assessment model for statins using multicriteria decision analysis based on a discrete choice experiment in Korean patients

摘要

PurposeThe benefit–risk balance for drugs can alter post approval owing to additional data on efficacy or adverse events. This study developed a quantitative benefit–risk assessment (BRA) model for statins using multicriteria decision analysis with discrete choice experiments and compared a recent BRA with that at the time of approval.